Robert W. Baird assumed coverage on shares of Pliant Therapeutics (NASDAQ:PLRX – Get Rating) in a research report sent to investors on Wednesday morning, The Fly reports. The brokerage issued an outperform rating and a $44.00 price target on the stock. Other equities research analysts also recently issued reports about the company. Citigroup cut their […]
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Rating) CEO Bernard Coulie sold 35,339 shares of Pliant Therapeutics stock in a transaction on Thursday, March 30th. The stock was sold at an average price of $26.52, for a total value of $937,190.28. Following the sale, the chief executive officer now owns 274,753 shares in the company, valued […]
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Rating) General Counsel Mike Ouimette sold 2,877 shares of Pliant Therapeutics stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $26.79, for a total transaction of $77,074.83. Following the completion of the sale, the general counsel now owns 50,789 […]
Should You Buy or Sell Pliant Therapeutics Stock? Get The Latest PLRX Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Rating) CEO Bernard Coulie sold 35,339 shares of the stock in a transaction dated Thursday, March 30th. The stock was sold at an average price of $26.52, for a total value of $937,190.28. Following the sale, the chief executive officer now owns 274,753 shares of the company’s stock, valued […]